Cas:1056056-12-2 N-3-azetidinylmethanesulfonamide manufacturer & supplier

Chemical Name:N-3-azetidinylmethanesulfonamide

CAS.NO:1056056-12-2

Synonyms:N-3-azetidinylmethanesulfonamide

Molecular Formula:C₄H₁₀N₂O₂S

Molecular Weight:150.19900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:66.58000

Exact Mass:150.04600

LogP:0.30790

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-3-azetidinylmethanesulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-3-azetidinylmethanesulfonamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-3-azetidinylmethanesulfonamide Use and application,N-3-azetidinylmethanesulfonamide technical grade,usp/ep/jp grade.

Related News: With its offering of API development, GMP manufacturing, solid state chemistry and analytical expertise, Onyx continues to experience strong growth driven by demand from biotech and pharmaceutical companies for its integrated CMC capabilities. (3α,5α)-3-methoxymethoxy-21-methyl-13,24-cyclo-18-norchol-20-ene manufacturers Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful. 3-(1-(4-chlorobenzyl)piperidin-4-yl)-5-(6-methoxyquinolin-4-yl)oxazolidin-2-one suppliers With its offering of API development, GMP manufacturing, solid state chemistry and analytical expertise, Onyx continues to experience strong growth driven by demand from biotech and pharmaceutical companies for its integrated CMC capabilities. 2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl-(1-)4)-3,6-di-O-benzyl-1,2-O-(1-methoxyethylidene)-α-D-glucopyranose vendor & factory The Global Talent Visa, along with the High Potential Individual and Scale-up visa routes in the Innovation Strategy, provide fast-track visa routes for high skills individuals and their teams, attracting top research talent to the UK. ,Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful.